Gold prices steady ahead of Fed decision; weekly weakness noted
ORLANDO - Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products with a market capitalization of $52.42 million, has been granted a patent in Macao for its AVERSA™ abuse deterrent technology. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.96, indicating robust financial flexibility to support its development initiatives. The patent, entitled "Abuse and Misuse Deterrent Transdermal Systems," was issued by the Macao Intellectual Property Office on February 11, 2025, and announced in the Macao Official Bulletin on March 5, 2025.
The AVERSA™ technology is designed to incorporate aversive agents into transdermal patches, aiming to prevent the abuse, diversion, misuse, and accidental exposure of drugs with potential for abuse, such as opioids and stimulants. This patent extends Nutriband's international intellectual property portfolio, with patents now issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, as well as the two Chinese SARs of Hong Kong and Macao.
Nutriband's partnership with Kindeva Drug Delivery is focused on developing AVERSA™ Fentanyl, which integrates the AVERSA™ technology into an FDA-approved transdermal fentanyl patch system. This product, if successful, could be the first abuse-deterrent opioid patch on the market, designed to reduce the risks associated with transdermal fentanyl patches.
The company's announcement highlighted the potential for AVERSA Fentanyl to achieve peak annual U.S. sales ranging from $80 million to $200 million, according to a 2022 market analysis report by Health Advances. However, these projections are contingent on various factors, including FDA approval and market acceptance.
The development of AVERSA™ technology aligns with ongoing efforts to enhance the safety profile of medications susceptible to abuse, ensuring they remain available for patients in need while mitigating the risks of misuse. With trailing twelve-month revenue of $2.02 million, Nutriband is actively pursuing growth opportunities in this specialized market. InvestingPro analysis suggests the stock is currently trading below its Fair Value, presenting a potential opportunity for investors interested in the pharmaceutical sector. Subscribers to InvestingPro can access 8 additional key insights about Nutriband's financial health and market position.
This news is based on a press release statement from Nutriband Inc. and does not include any endorsements of claims. The company's future plans, including the development and potential success of AVERSA™ Fentanyl, are subject to regulatory approval and market factors. Recent market data from InvestingPro shows the stock has experienced significant volatility, with a 12.59% decline over the past week, though maintaining a positive year-to-date return. For comprehensive analysis and real-time updates on Nutriband's market position, investors can explore additional metrics and expert insights available on InvestingPro.
In other recent news, Nutriband Inc. has made several significant strides in its development of transdermal pharmaceutical products. The company has received a Notice of Allowance from the United States Patent and Trademark Office for its AVERSA™ abuse deterrent technology, indicating that a patent will soon be granted. This development strengthens Nutriband's intellectual property rights in the U.S. for its portfolio of abuse deterrent transdermal products. Additionally, Nutriband has secured a trademark for "Nutriband™," associated with its AVERSA™ platform, further solidifying its brand in the pharmaceutical and biochemical fields.
Nutriband's partnership with Kindeva Drug Delivery is another key development, as both companies are collaborating to develop the AVERSA™ Fentanyl patch, a potential abuse-deterrent transdermal system. Market analysis by Health Advances suggests that this product could achieve peak annual sales in the U.S. of $80 million to $200 million. Furthermore, Nutriband has entered an Associate Partnership with Charlotte FC to enhance brand visibility, aligning with its local manufacturing efforts in North Carolina. These recent developments reflect Nutriband's ongoing commitment to innovation and its strategic focus on improving the safety profile of transdermal drugs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.